Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biotechnology company pioneering advancements in genome engineering. Leveraging revolutionary CRISPR-Cas9 technology, Caribou specializes in developing innovative cellular engineering solutions. Their technology, which pairs Cas9 with guide RNA to facilitate precise DNA modifications, is being harnessed for sophisticated gene knock-outs and knock-ins. Caribou's tools provide transformative capabilities across various sectors, including biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
At the forefront of biopharmaceutical innovation, Caribou is dedicated to applying its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform to create next-generation genome-edited cell therapies. Their pipeline includes allogeneic CAR-T and CAR-NK cell therapies, aimed at treating patients with hematologic malignancies and solid tumors.
Recent milestones include the FDA's feedback on a Phase 3 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting large B cell lymphoma (LBCL). The ongoing ANTLER Phase 1 trial has shown promising results, with CB-010 receiving Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations. Caribou is also expanding CB-010's potential application to lupus nephritis and extrarenal lupus, with a GALLOP Phase 1 trial planned for late 2024.
Financially, Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2026. Their strategic partnerships, including a collaboration with Pfizer, have bolstered their financial standing.
Caribou continues to push the boundaries of genome editing with its chRDNA technology, significantly improving the precision of genome edits. Their commitment to transforming patient lives through cutting-edge science positions them as a leader in the biotech landscape.
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, is scheduled to present at two events in June:
1. Jefferies Healthcare Conference in New York, NY on June 7, 2023, at 3:00 pm EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 13, 2023, at 3:20 pm PDT
Both presentations will be available via webcast. Interested parties can access the webcasts through the Events page on Caribou's website. The recordings will remain accessible for 30 days after each event.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2023 financial results and provided a business update. Key highlights include:
1. CB-010: Dose expansion in ANTLER Phase 1 trial for second-line LBCL patients; dose escalation data expected in H2 2023.
2. CB-011: CaMMouflage Phase 1 trial enrolling r/r MM patients; received Fast Track designation.
3. CB-012: IND application for r/r AML planned for H2 2023.
4. Financial position: $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; runway into 2025.
5. Q1 2023 results: Revenue $3.5 million, R&D expenses $25.7 million, G&A expenses $8.9 million, net loss $28.0 million.
Caribou Biosciences (Nasdaq: CRBU) announced promising preclinical results for CB-012, a CRISPR-edited CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (r/r AML), during the 2023 AACR Annual Meeting. The study indicated CB-012 shows enhanced antitumor activity, prolonged survival in AML xenograft models, and protective immune cloaking against NK cell-mediated cytotoxicity. The therapy is engineered with advanced Cas12a chRDNA technology, enabling five genomic edits for improved efficacy. Caribou plans to submit an IND application for CB-012 in H2 2023, signaling a key step in its clinical development strategy. CEO Rachel Haurwitz stated the data supports advancing CB-012 for clinical trials.
Caribou Biosciences (Nasdaq: CRBU) announced that the FDA has granted Fast Track designation to its investigational therapy, CB-011, for treating relapsed or refractory multiple myeloma (r/r MM). This designation facilitates communication with the FDA during the clinical review process. The CaMMouflage Phase 1 trial, which has recently commenced patient dosing, aims to develop CB-011 as an accessible off-the-shelf treatment option, eliminating the need for lengthy manufacturing and complex procedures. CB-011, derived from Caribou's CAR-T platform, employs advanced genome-editing techniques to enhance antitumor capabilities. The company continues to focus on developing cutting-edge therapies for serious diseases.
Caribou Biosciences (Nasdaq: CRBU) announced the first patient has been dosed in the CaMMouflage Phase 1 trial of CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at patients with relapsed or refractory multiple myeloma. This trial seeks to evaluate the safety and efficacy of the therapy, utilizing an innovative immune cloaking strategy to enhance antitumor activity by mitigating rejection from T and natural killer cells. As part of Caribou's aim to address unmet needs in treatment accessibility, the trial will include adults with extensive prior therapies. The company plans to continue patient enrollment to assess CB-011's therapeutic potential.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
What does Caribou Biosciences specialize in?
What is CB-010?
What recent FDA feedback did Caribou receive?
How is Caribou's financial health?
What is chRDNA technology?
What are the applications of Caribou's technology?
What designations has CB-010 received from the FDA?
What is the ANTLER trial?
What is Caribou's collaboration with Pfizer?
What upcoming trials are planned for CB-010?
